Our results suggest the validity and significance of molecular targeting agents for EGFR and/or VEGF pathway, and that further preclinical and clinical studies are warranted for improving the clinical outcome of cholangiocarcinoma. The gene discussed is EGFR; the disease is cholangiocarcinoma.